Role of Pemetrexed in Non-Small Cell Lung Cancer

REFERENCES

• Johnson D. H., Fehrenbacher L., Novotny W. F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2004; 22: 2184–2191
   PubMed Web of Science ®Google Scholar
• Theti D. S., Jackman A. L. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clin. Cancer. Res. 2004; 10: 1080–1089
   PubMed Web of Science ®Google Scholar
• Parker N., Turk M. J., Westrick E., Lewis J. D., Low P. S., Leamon C. P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 2005; 338: 284–293
   PubMed Web of Science ®Google Scholar
• Schultz R. M., Patel V. F., Worzalla J. F., Shih C. Role of the thymidylate synthase in the antitumor activity of the multitargeted antifolate LY231514. Anticancer Research 1999; 19: 437–443
   PubMed Web of Science ®Google Scholar
• Ouellet D., Periclou A. P., Johnson R. D., Woodworth J. R., Lalonde R. L. Population pharmacokinetics of pemetrexed disodium (Alimta) in patients with cancer. Cancer. Chemother. Pharmacol. 2000; 46: 227–234
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Chen V., Shih C., Menon K., Forler P. A., Phares V. G., Amsrud T. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenograft. Clin. Cancer Res. 2000; 6: 1016–1023
   PubMed Web of Science ®Google Scholar
• Britten C. D., Izbicka E., Hilsenbeck S., Lawrence R., Davidson K., Cerna C., Gomez L., Rowinsky E. K., Weitman S., Von Hoff D. D. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother. Pharmacol. 1999; 44: 105–110
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Alvarez E., Liu P., Lu K., Menon K., Dempsey J., Schultz R. M. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin. Oncol. 1999; 26: 55–56, (Suppl. 6)
   PubMed Web of Science ®Google Scholar
• Tonkinson J. L., Worzalla J. F., Teng C. H., Mendelsohn L. G. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 1999; 59: 3671–3676
   PubMed Web of Science ®Google Scholar
• Tesei A., Ricotti L., De Paola F., Amadori D., Frassinetti G. L. In vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin. Cancer Res. 2002; 8: 233–239
   PubMed Web of Science ®Google Scholar
• Rauchwerger D. R., Firby P. S., Hedley D. W., Moore M. J. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res. 2000; 60: 6075–6079
   PubMed Web of Science ®Google Scholar
• Giovannetti E., Mey V., Danesi R., Mosca I., Del Tacca M. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Cancer Res. 2004; 10: 2936–2943
   Web of Science ®Google Scholar
• Giovannetti E., Mey V., Nannizzi S., Pasqualetti G., Marini L., Del Tacca M., Danesi R. Cellular and pharmacogenetics foundation of Synergistic interaction of pemetrexed and gemcitabine in human non-small cell lung cancer cells. Mol. Pharmacol. 2005; 68: 110–118
   PubMed Web of Science ®Google Scholar
• Niyikiza C., Baker S. D., Seitz D. E. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 2002; 1: 545–552
   PubMed Web of Science ®Google Scholar
• Bajetta E., Celio L., Buzzoni R., Phase I I. study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann. Oncol. 2003; 14: 1543–1548
   PubMed Web of Science ®Google Scholar
• Bertino J. R., Banerjee D. Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time? Clin. Cancer Res. 2003; 4: 1235–1239
   Google Scholar
• Farrugia D. C., Ford H. E., Cunningham D. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin. Cancer Res. 2003; 9: 792–801
   PubMed Web of Science ®Google Scholar
• Olopade O. I., Buchhagen D. L., Malik K. Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res. 1993; 53: 2410–2415, (10 Suppl)
   PubMed Web of Science ®Google Scholar
• Rusthoven J. J., Eisenhauer E., Butts C., Gregg R., Dancey J., Fisher B., Iglesias J. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 1999; 17: 1194–1199
   PubMed Web of Science ®Google Scholar
• Clarke S. J., Abratt R., Goedhals L., Boyer M. J., Millward M. J., Ackland S. P., Phase I I. trial of pemetrexed disodium (Alimta, (LY 231514) in chemotherapy-native patients with advanced non-small-cell lung cancer. Ann. Oncol. 2002; 13: 737–741
   PubMed Web of Science ®Google Scholar
• Smit E. F., Mattson K., von Pawel J., Manegold C., Clarcke S., Postmus P. E. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann. Oncol. 2003; 14: 455–460
   PubMed Web of Science ®Google Scholar
• Hanna N., Shepherd F. A., Fossella F. V. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004; 22: 1589–1597
   PubMed Web of Science ®Google Scholar
• Cohen M. H., Johnson J. R., Wang Y-C., Sridara R., Pazdur R. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. The Oncologist 2005; 10: 363–368
   PubMed Web of Science ®Google Scholar
• Adjei A. A., Erlichman C., Sloan J. A., Phase I. and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumor. J. Clin. Oncol. 2000; 18: 1748–1757
   PubMed Web of Science ®Google Scholar
• Thodtman R., Depenbrock H., Dumez H., Blatter J., Johnson R. D., van Oosterom A., Hanauske A. R. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J. Clin. Oncol. 1999; 17: 3009–3016
   PubMed Web of Science ®Google Scholar
• Hughes A., Calvert P., Azzabi A., Phase I. clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2002; 20: 3533–3544
   PubMed Web of Science ®Google Scholar
• Missett J. L., Gamelin E., Campone M., Delaloge S., Latz J. E., Bozec L., Fumoleau P., Phase I. and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Ann. Oncol. 2004; 15: 1123–1129
   PubMed Web of Science ®Google Scholar
• Mackay H., Carmichael J., Roberts J. I Phase study of pemetrexed in combination with docetaxel in patients with advanced solid malignancies. Proc Am. Soc. Clin. Oncol. 2002; 21: 77b
   Google Scholar
• Clarke S. J., Boyer M. J., Millward M. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer 2005; 49: 401–412
   PubMed Web of Science ®Google Scholar
• Manegold C., Gatzemeier U., von Pawel J., Pirker R., Malayeri R., Blatter J., Krejcy K. Front-line treatment of advanced non small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann. Oncol. 2000; 11: 435–440
   PubMed Web of Science ®Google Scholar
• Shepherd F. A., Dancey J., Arnold A., Phase I I. study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trial Group. Cancer 2001; 92: 595–600
   PubMed Web of Science ®Google Scholar
• Zinner R. G., Fossella F. V., Gladish G. W., Phase I I. study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005; 104: 2449–2456
   PubMed Web of Science ®Google Scholar
• Scagliotti G. V., Korstsik C., Dark G. G. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin. Cancer Res. 2005; 11: 690–696
   PubMed Web of Science ®Google Scholar
• Monnerat C., Le Chevalier T., Kelly K., Phase I I. study of pemtrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin. Cancer Res. 2004; 10: 5439–5446
   PubMed Web of Science ®Google Scholar
• Ma C. X., Nair S., Thomas S. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small cell lung cancer. J. Clin. Oncol. 2005; 23: 5929–5937
   PubMed Web of Science ®Google Scholar
• Kelly K., Crowley J., Bunn P. A., Jr. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 2001; 19: 3210–3218
   PubMed Web of Science ®Google Scholar
• Schiller J. H., Harrington D., Belani C. P. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002; 346: 92–98
   Google Scholar
• Scagliotti G. V., De Marinis F., Rinaldi M. Italian Lung Cancer Project. III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 2002; 20: 4285–4291
   PubMed Web of Science ®Google Scholar
• Fossella F., Pereira J. R., von Pawel J. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 2003; 21: 3016–3024
   PubMed Web of Science ®Google Scholar
• Mao L. Recent advances in the molecular diagnosis of lung cancer. Oncogene 2002; 21: 6960–6969
   PubMed Web of Science ®Google Scholar
• Mitsudomi T., Steinberg S. M., Oie H. K. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 1991; 51: 4999–5002
   PubMed Web of Science ®Google Scholar
• Broermann P., Junker K., Brandt B. H., Heinecke A., Freitag L., Berdel W. E., Thomas M. Trimodality treatment in stage III non-small cell lung carcinoma: prognostic impact of K-ras mutations after neoadjuvant therapy. Cancer 2002; 94: 2055–2062
   PubMed Web of Science ®Google Scholar
• Khuri F. R., Lotan R., Kemp B. L. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small cell lung cancer. J. Clin. Oncol. 2000; 18: 2798–2804
   PubMed Web of Science ®Google Scholar
• Khuri F. R., Wu H., Lee J. J. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 2001; 7: 861–867
   PubMed Web of Science ®Google Scholar
• Shih J. Y., Yang S. C., Hong T. M. Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J. Natl. Cancer Inst. 2001; 93: 1392–1400
   PubMedGoogle Scholar
• Yuan A., Yang P. C., Yu C. J., Chen W. J., Lin F. Y., Kuo S. H., Luh K. T. Interleukin-8 messenger ribonuclein acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small cell lung cancer. Am. J. Respir. Crit. Care Med. 2000; 162: 1957–1963
   PubMed Web of Science ®Google Scholar
• Soria J. C., Moon C., Kemp B. L. Lack of interleukin-10 could predict poor outcome in patients with stage I non-small cell lung cancer. Clin. Cancer Res. 2003; 9: 1785–1791
   PubMed Web of Science ®Google Scholar
• Bepler G., Gautam A., McIntyre L. M. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small cell lung cancer. J. Clin. Oncol. 2002; 20: 1353–1360
   PubMed Web of Science ®Google Scholar
• Capiaux G. M., Budak-Alpdogan T., Alpdogan O. Protection of hemopoietic stem cell from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene. Cancer Gene Therapy 2004; 11: 767–773
   PubMed Web of Science ®Google Scholar
• May C., Gunther R., McIvor R. S. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood 1995; 86: 2439–2448
   PubMed Web of Science ®Google Scholar